Aug. 6 at 12:32 AM
$GH Guardant Health (GH) added nearly 10% at the market open on Friday to hit a new 52-week high after the blood-based cancer test maker reported Q2 2026 revenue well surpassing the consensus and raised its full-year outlook.
After the market close on Thursday, the Palo Alto, California-based firm posted
$335M in revenue for the quarter, beating estimates by
$20.6M with ~44% YoY growth as its oncology portfolio outperformed.
While its screening revenue reached
$52.9M with nearly 66K Shield screening tests delivered, up from
$14.8M and 16K tests in the prior-year period, its oncology portfolio added
$29.1M with 38% YoY growth compared with 28%- 29% in the guidance.
“Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year,” co-CEO Helmy Eltoukhy said. “Growth was fueled by strong oncology volume, with acceleration across every product,” he added.
